ClinicalTrials.gg
RecruitingNCT07381790MoT-LRTIUpdated Feb 2, 2026

Modern Technologies in Lower Respiratory Tract Infections in Children

An observational study in Bronchiolitis Acute, Lower Respiratory Tract and Lung Infections and Pediatric Lung Ultrasound, sponsored by Helse Møre og Romsdal HF. Recruiting at 2 sites in Norway. Open to participants aged 0 Days to 24 Months. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Helse Møre og Romsdal HF · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
0 Days to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Asthma with a site in Norway — 2 open to participants now, 3 under way, none of them phase 3. Asthma · Norway.

Started
2025
the only one that year
Observational
7 of 30
1 open now
Registered
30th of 30
by date
Lead sponsor
1 of 30
Helse Møre og Romsdal HF

Among the 30 studies in Asthma with a site in Norway, this one is the only one that started in 2025, is one of 7 observational ones, and was the 30th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 30 studies in Asthma with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 0 Days to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Asthma with a site in Norway, or all of them as a file.
02

Study summary

Lower respiratory tract infections (LRTIs) are a significant cause of childhood morbidity and mortality globally, particularly in low-income countries. In Norway, LRTIs is a leading cause of hospitalization among infants, representing a great socioeconomic burden.

Bronchiolitis, a viral infection, is the main representation of LRTIs in infants. It affects the small airways, causing breathing- and feeding difficulties. Today, treatment relies on subjective evaluations, lacking objective measures for assessment. This increases the risk of both under- and over treating patients. In the long term, bronchiolitis increases risk of asthma, but it is unknown who the high-risk patients for chronic lung disease are.

Lung ultrasonography (LUS) has emerged as a promising tool for assessing bronchiolitis severity and progression of the disease. The investigators will explore its use to improve diagnostic accuracy and treatment decisions, and develop AI-driven scoring tools for novel technology.

Additionally, tidal breathing flow volume loops (TBFVL) offer a non-invasive method for evaluating airway obstruction in infants, with the potential to assess severity of bronchiolitis, treatment efficacy and post-infection lung function.

In this project the investigators will combine the use of these modern technologies to improve treatment and follow-up of infants with LRTIs.

The main aim for this observational study is to assess the utility of lung ultrasonography (LUS) and tidal flow volume loops (TBFVL) in infant lower respiratory tract infections (LRTIs) for individual risk stratification in acute and chronic settings. This aims to refine the management of bronchiolitis, identifying high-risk patients for chronic lung disease to tailor treatment and follow-up protocols.

The project has three secondary objectives.

  1. To assess correlation between LUS and TBFVL findings with clinical score at admission, length of stay, need of respiratory support and ICU admissions.
  2. To assess duration of symptoms following acute bronchiolitis and evaluate the use of LUS and TBFVL in objectively examine post-infectious sequela.
  3. To evaluate the long-term impact of bronchiolitis on lung function through clinical follow-up after a 12 month period.

Lower respiratory tract infections (LRTIs) stand as the leading cause of hospitalization, while asthma is the leading cause of chronic lung disease among children in Nordic countries. The project seeks to improve risk stratification and treatment protocols in both acute and chronic settings.

In the acute setting, the project endeavors to prognosticate individual patient outcomes, thereby individualize treatment and mitigating unnecessary hospital admissions, use of respiratory support and antibiotic administration. Additionally there is potential of more aggressive treatment to selected patients. The study aims to improve the understanding of pathophysiological processes of LRTIs in infants, providing objective metrics to evaluate disease severity and individualize treatment.

The investigators aim to validate the utility, validity, and simplicity of handheld ultrasound devices as bedside diagnostic tools for this common disease, alongside affirming the value of tidal flow volume loops (TBFVL) in acute and chronic settings to assess airway obstruction in infants. Combining these modern technologies, evaluating affliction of both the parenchyme and the airways will probide a new perspective in treatment of LRTIs. In addition the project will strive to develop novel technology with AI-driven scoring tools of LUS.

Furthermore, the project aims to examine the trajectory of symptoms post-LRTI and facilitate the early identification of patients with high-risk of chronic lung disease. Early detection of asthma and other chronic lung diseases holds the potential to improve outcomes and mitigate the need for hospitalization, thus easing both economic and emotional burdens associated with the disease.

For caregivers, the lack of information concerning symptom duration and risk of future disease represents a significant knowledge gap. The project aims to address this, by examining post-infection symptom duration and identifying high-risk cohorts predisposed to chronic lung disease. This has the potential to both improve information, personalize follow-up and reduce hospital readmissions.

03

Conditions studied

  • Bronchiolitis Acute
  • Lower Respiratory Tract and Lung Infections
  • Pediatric Lung Ultrasound
  • Tidal Volume
  • Pediatric Lung Diagnosis
  • Pediatric Asthma

Keywords

  • pediatric
  • lung ultrasound
  • lower respiratory tract infections
  • tidal-flow volume loops
04

Who can participate

Ages eligible
0 Days to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

children under 2 years of age, hospitalized with lower respiratory tract infections. single cohort study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of lower respiratory tract infection
  • with tachypnea and/or
  • wheezing
  • Retractions
  • Respiratory difficulties

Exclusion criteria

Exclusion Criteria:

  • Severe Congenital heart disease (not ASD, small VSD, PDA)
  • Cystic fibrosis and PCD
  • Neuromuscular diseases and other diseases with reduced airway clearance
  • Severe malacia, diagnosed by bronchoscopy by time of T0.
  • Foreign body inhalation
  • Pneumothorax
  • Pleural effusion (with need of invasive interventions)
  • Bronchopulmonary dysplasia or GA \<32 weeks
  • Caretaker not able to communicate in Norwegian or English
  • Weight \<3 kg
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • children under 2 years of age, hospitalized with lower respiratory tract infection

    Diagnostic Test: lung ultrasound · Diagnostic Test: Tidal-flow volume loops

Interventions

  • Diagnostic testlung ultrasound

    performance of lung utltrasound in participants, performed bedside (v scan).

  • Diagnostic testTidal-flow volume loops

    tidal-flow volume loops performed in patients hospitalized with lower respiratory tract infections.

06

What researchers measure

Primary outcomes

  1. Number of readmissions at 1 year follow-up after baseline.

    All participants will be followed for 1 year after first hospitalization with LRTI. At that point investigators will retrieve data on readmissions as primary outcome, correlated with initial findings.

    Time frame: From enrollment to the end of follow-up at 12 months.

  2. Length of stay at hospital due to LRTI.

    Primay outcome is length of stay at hospital, correlated with findings at hospitalization (lung ultrasound and tidal-flow volume loops)

    Time frame: from enrollment to discharge from hospital, average patient is hospitalized 3 days.

  3. Duration of symptoms after hospitalization due to LRTI.

    duration of symptoms after hospitalization with lower respiratory tract infection, marked by symptom diary and follow-up by phone call. Participants are deemed free of symptoms when they are in habitual state without cough.

    Time frame: from enrollment to weeks/months after discharge, based on reporting of symptoms. Up to 60 days.

Secondary outcomes

  1. Use of respiratory support correlated with lung ultrasound score and tidal-flow volume loop results

    secondary outcome is degree of respiratory support correlated with findings on lung ultrasound (LUS) and tidal-flow volume loops (TBFVL). Investigators will monitor the use of NIV (HFNC, C-PAP, mechanical ventilation) in enrolled participants and correlate with results from TBFVL and scoring from LUS.

    Time frame: form enrollment to discharge from hospital, average hospitalization is 3 days.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 42 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Feb 2, 2026
StartActual
Dec 15, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07381790
Lead sponsor
Helse Møre og Romsdal HF
Collaborators
St. Olavs Hospital
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Dec 15, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Feb 2, 2026

Study contacts

Hans Kristian S Ipsen, medical doctor
Contact
hans.kristian.ipsen@helse-mr.no
+4770105000
Kari Risnes, Professor
Contact
kari.risnes@ntnu.no
+4772573000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion